Scholarlink

Background <p>Hepatoblastoma is the most common primary liver cancer in children. This study aims to estimate the global burden of hepatoblastoma in children from 1990 to 2021.</p> Methods <p>Data on the prevalence and DALYs among children with hepatoblastoma aged 0 to 4 years were downloaded from the Global Burden of Disease Study 2021. The average annual percentage change (AAPC) was calculated to evaluate the temporal trends.</p> Results <p>In 2021, there were 30,675 (95% UI: 17,025 to 39,606) cases and 179,107 (139,751 to 227,327) DALYs of hepatoblastoma among children aged 0 to 4 years globally. There were 40.3% and 50.8% decreases in hepatoblastoma cases and DALYs, respectively, from 1990 to 2021. Over the past 32 years, the global prevalence and DALY rates of hepatoblastoma have significantly decreased, with AAPCs of -1.83 (95% CI: -2.06 to -1.59) and  -2.44 (95% CI: -2.55 to -2.34), respectively. Western Sub-Saharan Africa and high-income North America had the highest prevalence rates in 2021. Countries with high socio-demographic index in 2021 had lower DALY rates of hepatoblastoma.</p> Conclusion <p>The global burden of hepatoblastoma in children has shown a downward trend, with the burden differing across regions. These results provide comparable estimates that can potentially inform efforts toward hepatoblastoma control in children.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Global prevalence and disability-adjusted life years of hepatoblastoma in children aged 0 to 4 years

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月30日

查看全文
  • Wenkai Jiang,
  • Huiqi Sun,
  • Tianxin Zhao,
  • Hanxin Li,
  • Bingwen Yan,
  • Yanxin An

摘要

Background

Hepatoblastoma is the most common primary liver cancer in children. This study aims to estimate the global burden of hepatoblastoma in children from 1990 to 2021.

Methods

Data on the prevalence and DALYs among children with hepatoblastoma aged 0 to 4 years were downloaded from the Global Burden of Disease Study 2021. The average annual percentage change (AAPC) was calculated to evaluate the temporal trends.

Results

In 2021, there were 30,675 (95% UI: 17,025 to 39,606) cases and 179,107 (139,751 to 227,327) DALYs of hepatoblastoma among children aged 0 to 4 years globally. There were 40.3% and 50.8% decreases in hepatoblastoma cases and DALYs, respectively, from 1990 to 2021. Over the past 32 years, the global prevalence and DALY rates of hepatoblastoma have significantly decreased, with AAPCs of -1.83 (95% CI: -2.06 to -1.59) and  -2.44 (95% CI: -2.55 to -2.34), respectively. Western Sub-Saharan Africa and high-income North America had the highest prevalence rates in 2021. Countries with high socio-demographic index in 2021 had lower DALY rates of hepatoblastoma.

Conclusion

The global burden of hepatoblastoma in children has shown a downward trend, with the burden differing across regions. These results provide comparable estimates that can potentially inform efforts toward hepatoblastoma control in children.